Enabling scalable, GMP-ready CGT manufacturing

What are the main uses of benchtop bioreactors and single-use fermentors in CGT, and how do they support scale-up to clinical production?

We’re most commonly seeing single-use fermentors in the 2–10 L range being used for E. coli–based fermentation, particularly for plasmid DNA production in gene therapy workflows. One of the major shifts we’re seeing in fermentation has been the willingness of our customers to move away from traditional glass or autoclavable vessels to single-use systems.

That transition allows scientists to spend far more time focusing on the science and the process itself, rather than on vessel preparation, sterilization, and cleanup. In many cases, what used to take days for setup and turnaround can now be done in an hour or less, which significantly accelerates early development and supports smoother scale-up toward clinical manufacturing.

How do bioprocess controllers enhance the reproducibility and efficiency of CGT production using benchtop and single-use bioreactors, particularly for suspension and adherent cell lines?

A robust bioprocess controller is really the backbone of reproducible CGT manufacturing. Developing a process on a controller that is consistent, reliable, and scalable ensures that critical parameters (like pH, DO, temperature, and feeding strategies) are tightly controlled and repeatable across runs.

For both suspension and adherent cell processes, this consistency translates directly into improved efficiency, higher confidence in data, and smoother tech transfer as processes move from development into later-stage production.

How can benchtop bioreactors and single-use fermentors be adapted to accommodate the evolving requirements of different CGT modalities, such as viral vector production or stem cell expansion?

Flexibility and customization are essential in the CGT space, especially as modalities and processes continue to evolve. At Distek, our benchtop single-use solutions are designed to be highly customizable in a timely and cost-effective manner.

Whether a customer needs different fluid connections to transition from a fed-batch to a perfusion process, or a downtube added to support media exchange during stem cell expansion on microcarriers, our systems can be adapted to meet those specific process requirements without forcing the customer into a one-size-fits-all solution.

How do single-use bioreactors improve flexibility, contamination control and turnaround in CGT processes compared to traditional stainless-steel systems?

Traditional stainless-steel systems and glass autoclavable vessels require extensive setup, sterilization, cleaning and validation. Each of those steps consumes time, energy, and resources, while also introducing additional contamination risk.

Single-use bioreactor platforms significantly reduce that burden. By eliminating SIP/CIP and autoclaving steps, users can achieve faster batch turnaround, lower contamination risk, and more flexible workflows. This ultimately allows scientists and engineers to spend more time optimizing the process and less time on setup and teardown.

What regulatory considerations should be addressed when implementing benchtop and single-use bioreactors for GMP-compliant CGT manufacturing?

From a regulatory standpoint, having a robust supervisory control and data acquisition (SCADA) strategy is critical. The system must support secure data handling, audit trails, electronic records, and reliable integration of PAT tools to meet cGMP requirements.

At Distek, we recognize that customers are at different stages when it comes to the regulatory needs of a benchtop bioreactor system. That’s why we’re actively developing our own SCADA platform to provide a validated, CGT-focused solution, while also maintaining an open architecture through open platforms communication (OPC). This allows customers to integrate Distek systems into virtually any third-party SCADA environment they may already be using.

This combination gives users the flexibility to meet current GMP and data integrity expectations, while also future-proofing their processes as regulatory requirements and digital strategies continue to evolve.

What are the latest technological advancements that address the unique challenges of CGTS, such as real-time monitoring, automation, and process scalability?

At Distek, our focus has been on building systems that are both extremely flexible and highly reliable. New process analytical technologies (PAT) are constantly emerging to improve real-time monitoring, automation, and scalability in CGT manufacturing.

Having a bioreactor platform that can easily integrate these evolving technologies (without sacrificing robustness or usability) is key to supporting both current needs and future process development.

How can Distek’s technologies be leveraged to accelerate CGT process development, and what advantages does their system architecture offer in terms of adaptability and ease of technology transfer?

Distek’s platform is really designed to meet customers where they are in their CGT development journey. Our benchtop bioreactors and single-use systems give users the flexibility to move quickly in early process development, while still maintaining a clear path toward scale-up and tech transfer.

The BIOne 1250’s architecture is intentionally open and adaptable. Customers can customize single-use assemblies, integrate a wide range of PAT tools, and configure control strategies that match their specific process needs, rather than being locked into a rigid, closed platform.

Just as importantly, ease of use has always been our major focus. From intuitive software to straightforward system setup, these priorities help teams generate high-quality, reproducible data faster. Combined with strong service and application support, this allows CGT developers to spend less time troubleshooting equipment and more time optimizing their process as it evolves.